A recent observational study examining ivermectin and mebendazole as a potential cancer treatment has sparked debate, with UK health expert Dr John Campbell describing the findings as “remarkable” and questioning why larger trials have not been carried out.
The study followed 197 cancer patients who took daily doses of the two drugs for 90 days, reporting a clinical benefit rate of about 84%, while only 15.6% experienced disease progression.
Researchers found that nearly half of participants reported tumour regression or no evidence of disease, with others experiencing stable conditions across a wide range of cancers.
Campbell said the results “drive you mad really” given the absence of large-scale randomised trials, arguing the research signals a need for further investigation.
While side effects were reported as generally mild and adherence was high, researchers emphasised that controlled clinical trials are still required to confirm effectiveness, safety, and appropriate dosing before any firm conclusions can be made.
